- Silo Pharma announced CIPO has issued a Notice of Allowance for a patent application covering SPC-15, its intranasal 5-HT4 receptor agonist targeting PTSD and other stress-induced psychiatric disorders.
- The patent covers methods to prevent or delay stress-induced fear and depressive-like behavior and enhance stress resilience by administering selected 5-HT4 agonists before a stressor.
- Silo holds an exclusive license to the Canadian application through its broader Columbia University agreement to develop, manufacture and commercialize SPC-15 globally. Related IP is also advancing internationally.
- With corresponding protection granted or advancing across multiple markets, including a recently granted European patent, Silo plans to pursue the FDA’s 505(b)(2) pathway, potentially shortening timelines and reducing costs.
Takeaways:
Silo Pharma’s CIPO Notice of Allowance for SPC‑15 strengthens its IP moat around a prophylactic, intranasal 5‑HT4 agonist approach for PTSD and stress‑induced disorders, complementing a recently granted European patent and supporting a global development strategy. 1005 By planning an FDA 505(b)(2) pathway—leveraging existing data on 5‑HT4 agonists and its novel intranasal delivery—Silo aims to shorten timelines and reduce development costs, which could make SPC‑15 more attractive for partnerships or licensing as it advances toward an IND and early clinical testing.
Source: Globenewswire
